Trial register facet
Trial records for Semaglutide
71 records for Semaglutide, of which 16 are published trials.
Showing 0 records on this page
Records
71 documents · page 1 of 3
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| STRIDE | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 792 | 2025 | Moderate |
| ESSENCE | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,197 | 2025 | Moderate |
| ESSENCE-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| STRIDE-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ESSENCE-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| STRIDE-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| STRIDE-REGIONAL-JPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ESSENCE-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| STEP-HFpEF-DM | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 616 | 2024 | Moderate |
| FLOW | Semaglutide | Phase 3 | Reported | Event-driven kidney outcome trial | 3,533 | 2024 | High |
| STEP-HFpEF-DM-BODY-COMPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| FLOW-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| FLOW-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| FLOW-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| STEP-HFpEF | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 529 | 2023 | Moderate |
| SELECT | Semaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 17,604 | 2023 | High |
| STEP-HFpEF-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SELECT-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2023 | Very low |
| STEP-HFpEF-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| STEP-5 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 304 | 2022 | High |
| STEP-8 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 338 | 2022 | High |
| STEP-TEENS | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 201 | 2022 | Moderate |
| STEP-5-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-8-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
page 1 of 3